Your partner for Antibody Discovery and Humanisation
With 30 years of experience, a 98% success rate in antibody humanization, and five antibody drugs on the market (e.g., Keytruda, Tysabri, Leqembi), LifeArc is dedicated to advancing innovative therapies. Our newly launched B-SMArT antibody discovery platform offers collaborators a clinically validated transgenic mouse model (Kymab/Sanofi) and advanced single B-cell selection technologies (Beacon and FACS) to generate fully human antibodies ready for in vivo testing
Our partnership model
LifeArc adopts a flexible, collaborative approach with our partners:
- Progress your project at no cost: We assume the financial risk, fully funding projects with strong scientific rationale and clear routes to market.
- Stay involved at every step: We maintain open dialogue and provide frequent sample sharing throughout the collaboration.
- Retain your intellectual property: You keep IP ownership and commercialisation control after the project ends, with additional post-delivery guidance—such as patent support—available if needed.
Eligibility
- Academics who are working on a therapeutic target or have developed antibodies against it and seek further optimisation toward IND submission and clinical trials.
- Biotech SMEs who would like to leverage LifeArc’s expertise in antibody humanisation and discovery.
Background information:
Read more about our offering for Antibody Discovery and Humanization
How to submit your interest
Reach out to our Business Development team at [email protected], and we will arrange a call to discuss your project proposal in detail.